Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Unquoted Biotechs -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (151)	9/26/2006 9:16:22 AM
From: Ian@SI	Respond to of 253

Couple Quark stories: One with ALNY, another with PFE. ++++++++++++++ Alnylam Grants Quark License To Develop Two RNAi Products djones DOW JONES NEWSWIRES Alnylam Pharmaceuticals Inc. (ALNY) granted privately held Quark Biotech Inc. licenses to discover, develop and commercialize RNAi therapeutics targeting the p53 and RTP801 genes for certain diseases. Terms of the deal weren't disclosed. However, Alnylam said the transaction includes upfront, annual, and milestone payments, as well as royalties on sales. The company also said Quark agreed to withdraw its opposition to the Kreutzer- Limmer patent series currently granted in Europe. Alnylam, Cambridge, Mass., said Quark, Fremont, Calif., has filed investigational new drug applications for both targets, specifically in the case of p53 for the treatment of renal failure and RTP801 for the treatment of ocular diseases. Earlier Tuesday, Quark entered into an agreement with Pfizer Inc. (PFE) in which the New York-based pharmaceutical company acquired exclusive license to Quark's RTP801 human gene and to molecules that modify its expression or function. The agreement between Quark and Pfizer is subject to clearance by the Federal Trade Commission. Terms of that deal weren't disclosed.